Study design for a randomized controlled trial of osmotic-release methylphenidate (OROS-MPH) for Attention Deficit Hyperactivity Disorder in adolescents with substance use disorders.
This presentation about CTN-0028 (Osmotic-Release Methylphenidate for ADHD in Adolescents with Substance Use Disorders) describes the study’s objectives, design, sites and participants, and primary outcome measures.
It also offers an overall timeline for the project, as well as an update on the progress of Wave 1.
Related protocols: CTN-0028
Categories:
Adolescents, Attention Deficit Hyperactivity Disorder (ADHD), Co-occurring disorders, CTN protocol development, Pharmacological therapy, Research design
Authors:
Winhusen, T. John
Source:
Presented at the New Clinical Drug Evaluation Unit (NCDEU) annual meeting, June 12-15, 2006